Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BB102 in advanced solid tumors
NCT06258408Phase 1Recruiting
- Sponsor
- BroadenBio Co., Ltd.
- Start
- Dec 2022
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BB102 in solid tumor (advanced stage) and hepatocellular carcinoma (HCC), sponsored by BroadenBio Co., Ltd. Primary endpoints: Dose Limiting Toxicities at 21 days, Adverse Events at 12 months and 1 more. Started Dec 2022; status: recruiting.
02
Drugs
BB102
03
Conditions
solid tumor (advanced stage)hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06258408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06258408.